- Stocks
- Pharma & Healthcare
- NGL Fine-Chem
NGL Fine-Chem share price
NSE: NGLFINEPharma & HealthcareDrug Manufacturers - General
NGL Fine-Chem at a glance
NGL Fine-Chem (NSE: NGLFINE) closed at ₹2,717.20 on 22 Oct 2026, up 3.00% on the day. With a market capitalisation of ₹1,679 Cr, it ranks 1211th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 34.8× trailing earnings, against a return on equity of 14.6% in FY26. Over the past year the share price has risen 80.2%. Its 52-week range is ₹1,271.00 (19 Dec 2025) to ₹3,602.00 (12 Aug 2026); the last close is 24.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹149 Cr (+57.1% year on year) and net profit ₹13 Cr (+2,398.1%), on a consolidated basis. Promoters held 72.49% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,679 CrRank 1211 on NSE
- P/E (trailing)
- 34.8×
- Price to book
- 3.89×FY26
- EPS (TTM)
- ₹77.77to Q4 FY26
- ROE
- 14.6%FY26
- ROCE
- 17.2%FY26
- Debt to equity
- 0.33FY26
- Net profit margin
- 9.6%FY26
- Book value / share
- ₹532.91FY26
- 52-week high
- ₹3,602.0012 Aug 2026
- 52-week low
- ₹1,271.0019 Dec 2025
- 1-year return
- +80.2%
- RSI (14-day)
- 42.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +3.00% | −5.2% | −0.5% | −15.4% | +80.2% |
NGL Fine-Chem quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹91 Cr | ₹93 Cr | ₹89 Cr | ₹95 Cr | ₹104 Cr | ₹120 Cr | ₹128 Cr | ₹149 Cr |
| Revenue YoY | +27.7% | +16.6% | +1.3% | −4.8% | +14.8% | +28.6% | +43.1% | +57.1% |
| Net profit | ₹9 Cr | ₹10 Cr | ₹1 Cr | ₹1 Cr | ₹9 Cr | ₹10 Cr | ₹16 Cr | ₹13 Cr |
| Net profit YoY | +8.3% | −6.4% | −87.2% | −95.6% | +0.2% | −1.8% | +1,125.8% | +2,398.1% |
| Net margin | 10.2% | 10.5% | 1.4% | 0.6% | 8.9% | 8.0% | 12.3% | 9.0% |
| EPS | ₹14.92 | ₹15.88 | ₹2.07 | ₹0.88 | ₹14.96 | ₹15.58 | ₹25.40 | ₹21.83 |
NGL Fine-Chem financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹258 Cr | ₹318 Cr | ₹278 Cr | ₹339 Cr | ₹368 Cr | — |
| Operating profit | ₹78 Cr | ₹67 Cr | ₹27 Cr | ₹54 Cr | ₹28 Cr | — |
| Net profit | ₹57 Cr | ₹50 Cr | ₹21 Cr | ₹41 Cr | ₹21 Cr | — |
| EPS (₹) | ₹92.00 | ₹81.00 | ₹33.00 | ₹67.00 | ₹34.00 | — |
| Cash from operations | ₹27 Cr | ₹14 Cr | ₹35 Cr | ₹20 Cr | ₹36 Cr | — |
| Total debt | ₹6 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹25 Cr | ₹56 Cr |
| Shareholders' equity | ₹154 Cr | ₹203 Cr | ₹223 Cr | ₹263 Cr | ₹282 Cr | ₹329 Cr |
NGL Fine-Chem shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.49% |
| Foreign institutions | 0.00% | 0.00% | 0.00% | — | 0.03% | 0.05% |
| Domestic institutions | 0.00% | 0.00% | — | — | — | 0.02% |
| Non-institutions | 27.26% | 27.26% | 27.26% | 27.26% | 27.24% | 27.43% |
NGL Fine-Chem vs peers
The listed Pharma & Healthcare companies nearest to NGL Fine-Chem by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| HESTERBIOHester Biosciences | ₹2,165.00 | −0.37% | +25.4% | ₹1,842 Cr | 32 | — |
| WINDLASWindlas Biotech | ₹885.70 | −0.20% | −2.2% | ₹1,828 Cr | 28.4 | — |
| TITANBIOTitan Biotech | — | — | — | ₹1,793 Cr | — | — |
| FISCHERFischer Medical Ventures | ₹26.21 | +3.80% | −72.0% | ₹1,715 Cr | 58.2 | — |
| NGLFINENGL Fine-Chem | ₹2,717.20 | +3.00% | +80.2% | ₹1,679 Cr | 34.8 | — |
| KRSNAAKrsnaa Diagnostics | ₹510.75 | −0.79% | −38.5% | ₹1,657 Cr | 16.5 | — |
| JLHLJupiter Life Line Hospitals | ₹244.75 | −0.87% | −20.0% | ₹1,605 Cr | 8.3 | — |
Ask anything about NGL Fine-Chem
Pivot answers on the live chart with evidence you can check, and tests strategies against NGLFINE's own history. Try: “Why has NGLFINE moved over the last three months?” · “Backtest a 50-day moving-average crossover on NGLFINE over five years” · “Compare NGLFINE with HESTERBIO on margins and valuation”
Frequently asked questions about NGL Fine-Chem
What is the share price of NGL Fine-Chem today?
NGL Fine-Chem (NSE: NGLFINE) last closed at ₹2,717.20 on 22 Oct 2026. Its 52-week high is ₹3,602.00 and its 52-week low is ₹1,271.00.
What is the market cap of NGL Fine-Chem?
NGL Fine-Chem's market capitalisation is ₹1,679 Cr (₹1,679 Cr) at the 22 Oct 2026 close, ranking 1211th among the NSE companies Pivot tracks.
What is the P/E ratio of NGL Fine-Chem?
NGL Fine-Chem trades at a trailing P/E of 34.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 28.4.
What is the ROE and ROCE of NGL Fine-Chem?
Return on equity was 14.6% in FY26 and return on capital employed was 17.2% in FY26 (consolidated figures).
Is NGL Fine-Chem a debt-free company?
No. NGL Fine-Chem's debt-to-equity ratio was 0.33 in FY26, with total debt of ₹56 Cr.
What were NGL Fine-Chem's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), NGL Fine-Chem reported revenue of ₹149 Cr, +57.1% year on year, and net profit of ₹13 Cr, +2,398.1% year on year.
How has NGL Fine-Chem stock performed over the last year?
NGL Fine-Chem's share price has risen 80.2% over the past year, −15.4% over three months and −0.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of NGL Fine-Chem?
As of 30 Jun 2026: promoters 72.49%, foreign institutions 0.05%, domestic institutions 0.02%, non-institutions 27.43%.
Who are NGL Fine-Chem's competitors?
The listed Pharma & Healthcare companies closest to NGL Fine-Chem by market cap are Hester Biosciences, Windlas Biotech, Titan Biotech, Fischer Medical Ventures, Krsnaa Diagnostics and Jupiter Life Line Hospitals.
Is NGL Fine-Chem a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out NGL Fine-Chem's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NGLFINE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text